Hill-Rom (HRC) Receiving Somewhat Positive Media Coverage, Accern Reports

News headlines about Hill-Rom (NYSE:HRC) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hill-Rom earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the medical technology company an impact score of 45.9544017369685 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

Hill-Rom stock traded up $1.11 during midday trading on Monday, hitting $85.56. 314,596 shares of the stock were exchanged, compared to its average volume of 522,722. Hill-Rom has a fifty-two week low of $69.47 and a fifty-two week high of $91.11. The stock has a market cap of $5,588.37, a P/E ratio of 22.17, a PEG ratio of 1.36 and a beta of 0.97. The company has a current ratio of 1.75, a quick ratio of 1.29 and a debt-to-equity ratio of 1.39.

Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.13. The company had revenue of $669.70 million during the quarter, compared to analyst estimates of $670.00 million. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. Hill-Rom’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. analysts forecast that Hill-Rom will post 4.62 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 23rd were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend was Thursday, March 22nd. This is a positive change from Hill-Rom’s previous quarterly dividend of $0.18. Hill-Rom’s dividend payout ratio (DPR) is 20.73%.

Several research firms recently issued reports on HRC. KeyCorp restated a “buy” rating and set a $94.00 price objective on shares of Hill-Rom in a research report on Thursday, December 21st. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price objective for the company in a research report on Wednesday, January 3rd. Morgan Stanley cut shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Zacks Investment Research cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $105.00 price objective (up from $90.00) on shares of Hill-Rom in a research report on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $93.89.

ILLEGAL ACTIVITY NOTICE: “Hill-Rom (HRC) Receiving Somewhat Positive Media Coverage, Accern Reports” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/10/hill-rom-hrc-receiving-somewhat-positive-media-coverage-accern-reports.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.

Insider Buying and Selling by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply